Triumvira Presents Data on T Cell Antigen Coupler (TAC) Technology at the 6th Annual Immuno-Oncology Summit
TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors AUSTIN, TX, and HAMILTON, ON, August 30, 2018 – Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on...Read More >>